Overview

MDMA-assisted Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder

Status:
Not yet recruiting

Trial end date:
2025-07-01

Target enrollment:

Participant gender:

Summary

In partnership with the Veterans Affairs (VA) Palo Alto Health Care System and Stanford University, this study aims to evaluate clinical outcomes, assess implementation feasibility, and health economics of MDMA-assisted therapy in the treatment of posttraumatic stress disorder (PTSD). Through a randomized comparison of MDMA-assisted therapy versus Cognitive Processing Therapy (CPT), a VA gold standard treatment for PTSD, the proposed study will set the stage for understanding the potential use and application of MDMA-assisted therapy for PTSD within the VA system.

Phase:

Phase 2

Details

Lead Sponsor:

Patricia Suppes

Collaborators:

Stanford University
Steven & Alexandra Cohen Foundation
VA Palo Alto Health Care System

Treatments:

N-Methyl-3,4-methylenedioxyamphetamine